References
1. Sievers BL, Chakraborty S, Xue Y et al . Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci Transl Med2022; eabn7842.
2. Kumar S, Thambiraja TS, Karuppanan K et al . Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.J Med Virol 2021; Dec 15. doi: 10.1002/jmv.27526.
3. García-Fiñana M, Hughes DM, Cheyne CP  et al . Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study. BMJ2021; 374: n1637.
4. Couzin-Frankel J. Antiviral pills could change pandemic’s course. Science 2021; 374: 799-800.
5. Ledford H. COVID antiviral pills: what scientists still want to know. Nature 2021; 599:358-9.
6. Owen DR, Allerton CMN, Anderson AS et al . An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 2021; 374: 1586-93.
7. ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis 2021; : S1473-3099(21)00751-9.
8. Kotecha T, Knight DS, Razvi Y et al . Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J 2021;42: 1866-78.
9. Sultanian P, Lundgren P, Strömsöe A et al . Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation. Eur Heart J 2021; 42:1094-106.
10. Butt JH, Fosbøl EL, Gerds TA et al . All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study. Eur Heart J 2021; 42: 1516-23.
11. Xie Y, Xu E, Bowe B et al . Long-term cardiovascular outcomes of COVID-19.  Nat Med  2022; https://doi.org/10.1038/s41591-022-01689-3
12. Baum A, Fulton BO, Wloga E et al . Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 2020; 369: 1014-8.
13. Li Q, Wu J, Nie J et al . The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.Cell 2020; 182: 1284-1294.
14. Loizides U, Adisa A, de la Rica Manjavacas AL et al . WHO international non-proprietary names: the need to distinguish COVID-19 vaccines. Lancet 2021; 397: 577-8.
15. Love TJ, Wessman I, Gislason GK et al . The first wave of COVID-19 and concurrent social restrictions were not associated with a negative impact on mental health and psychiatric well-being. J Intern Med 2022; Feb 2.
doi: 10.1111/joim.13461.
16. Martin-Vicente M, Almansa R, Martínez I et al . Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. J Intern Med 2022; 291: 232-40. doi: 10.1111/joim.13386.
17. Di Maio S, Lamina C, Coassin S et al. Lipoprotein(a) and SARS-CoV-2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events. J Intern Med 2022; 291: 101-7.
18. Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA 2021; 325:780-1.
19. Widge AT, Rouphael NG, Jackson LA et al . mRNA-1273 Study Group. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med2021; 384: 80-2.
20. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med 2021;27: 205-11.
21. Li Y, Renner DM, Comar CE, Whelan JN, Reyes HM, Cardenas-Diaz FL, Truitt R, Tan LH, Dong B, Alysandratos KD, Huang J, Palmer JN, Adappa ND, Kohanski MA, Kotton DN, Silverman RH, Yang W, Morrisey EE, Cohen NA, Weiss SR. SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes. Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):e2022643118.
doi: 10.1073/pnas.2022643118. PMID: 33811184
22. Kothari H, Williams CM, McSkimming C, Drago F, Marshall MA, Garmey J, Vigneshwar M, Zunder ER, McNamara CA. Identification of human immune cell subtypes most responsive to IL-1beta-induced inflammatory signaling using mass cytometry. Sci Signal. 2021 Mar 9;14(673):eabc5763.
doi: 10.1126/scisignal.abc5763. PMID: 33688079
23. Ordonez AA, Wintaco LM, Mota F, Restrepo AF, Ruiz-Bedoya CA, Reyes CF, Uribe LG, Abhishek S, D’Alessio FR, Holt DP, Dannals RF, Rowe SP, Castillo VR, Pomper MG, Granados U, Jain SK. Imaging Enterobacterales infections in patients using pathogen-specific positron emission tomography. Sci Transl Med. 2021 Apr 14;13(589):eabe9805. doi: 10.1126/scitranslmed.abe9805. PMID: 33853931
24. Wu M, Wall EC, Carr EJ et al . Three-dose vaccination elicits neutralising antibodies against omicron. Lancet  2022;399: 715-7.
25. Lamontagne F, Agoritsas T, Siemieniuk R et al . A living WHO guideline on drugs to prevent covid-19. BMJ  2021; 372: n526.
26. Greaney AJ, Loes AN, Gentles LE et al . Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci Transl Med 2021;13: eabi9915.
27. Wu Y, Huang X, Yuan L et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci Transl Med 2021; 13: eabg1143.
28. Francica JR, Flynn BJ, Foulds KE et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci Transl Med 2021;13: eabi4547.
29. van Doremalen N, Purushotham JN, Schulz JE et al . Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med 2021; 13: eabh0755.
30. Urbanowicz RA, Tsoleridis T, Jackson HJ et al . Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Sci Transl Med2021; 13: eabj0847.
31. Atyeo C, DeRiso EA, Davis C et al . COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. Sci Transl Med 2021; 13: eabi8631.
32. Tostanoski LH, Yu J, Mercado NB et al . Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. Sci Transl Med 2021;13: eabj3789.
33. Swanson PA 2nd, Padilla M, Hoyland W et al . AstraZeneca/Oxford/VRC Study Group. AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T(H)1 response with a diverse TCR repertoire. Sci Transl Med2021; 13: eabj7211.
34. Lanini S, Capone S, Antinori A et al . GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Sci Transl Med 2022;14: eabj1996.
35. Staub K, Panczak R, Matthes KL, et al. Historically High Excess Mortality During the COVID-19 Pandemic in Switzerland, Sweden, and Spain. Ann Intern Med 2022: M21-3824. doi: 10.7326/M21-3824.
36. Delgado MK, Morgan AU, Asch DA et al . Comparative Effectiveness of an Automated Text Messaging Service for Monitoring COVID-19 at Home. Ann Intern Med 2022; 175:179-190.
37. Mevorach D, Anis E, Cedar N et al . Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med2021; 385: 2140-9.
38. Lai FTT, Li X, Peng K et al . Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine: A Case-Control Study. Ann Intern Med2022: M21-3700. doi: 10.7326/M21-3700.
39. See I, Lale A, Marquez P et al . Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021. Ann Intern Med 2022: M21-4502.
doi: 10.7326/M21-4502.
40. Qaseem A, Yost J, Etxeandia-Ikobaltzeta I et al . Scientific Medical Policy Committee of the American College of Physicians*. What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med2022:M21-3272.
doi: 10.7326/M21-3272.
41. Gazit S, Shlezinger R, Perez G et al . The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study. Ann Intern Med 2022: M21-4130. doi: 10.7326/M21-4130.
42. Kang M, Yi Y, Li Y et al . Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China: A Cohort Study. Ann Intern Med 2022; M21-3509. doi: 10.7326/M21-3509.
43. Kumar D, Ferreira VH, Hall VG et al . Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine: Secondary Analysis of a Randomized Trial.Ann Intern Med 2022; 175: 226-33.
doi: 10.7326/M21-3480.
44. Chakraborty S, Gonzalez JC, Sievers BL, et al. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Sci Transl Med. 2022;eabm7853. PMID: 35040666
45. May CN, Bellomo R, Lankadeva YR. Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19. Br J Pharmacol. 2021;178(19):3864-3868. doi: 10.1111/bph.15579. .. PMID: 34061355
46. Tree JA, Turnbull JE, Buttigieg KR, Elmore MJ, Coombes N, Hogwood J, Mycroft-West CJ, Lima MA, Skidmore MA, Karlsson R, Chen YH, Yang Z, Spalluto CM, Staples KJ, Yates EA, Gray E, Singh D, Wilkinson T, Page CP, Carroll MW. Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. Br J Pharmacol. 2021;178(3):626-635.
doi: 10.1111/bph.15304… PMID: 33125711
47. Subramaniam S, Ruf W, Bosmann M. Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019. Br J Pharmacol. 2021;
doi: 10.1111/bph.15587. . PMID: 34235728
48. Jodele S, Köhl J. Tackling COVID-19 infection through complement-targeted immunotherapy. Br J Pharmacol. 2021;178(14):2832-2848.
doi: 10.1111/bph.15187.. PMID: 32643798
49. Cinar R, Iyer MR, Kunos G. Dual inhibition of CB(1) receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19. Br J Pharmacol. 2021 Mar 26:10.1111/bph.15461.
doi: 10.1111/bph.15461… PMID: 33769552
50. Lozano B, Santibañez J, Severino N, Saldias C, Vera M, Retamal J, Torres S, Barrera NP. Hypothesis: How far are we from predicting multi-drug interactions during treatment for COVID-19 infection? Br J Pharmacol. 2022 Feb 18.
doi: 10.1111/bph.15819. .. MID: 35180811
51. Zamai L, Rocchi MBL. Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine. Br J Pharmacol. 2022 Jan;179(2):218-226.
doi: 10.1111/bph.15620. .. PMID: 34331459